Ciprofibrate in the therapy of type II hypercholesterolemia A double-blind trial
- 31 July 1982
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 44 (2), 211-221
- https://doi.org/10.1016/0021-9150(82)90115-0
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrateAtherosclerosis, 1981
- Fenofibrate therapy of hyperlipoproteinaemia a dose—response study and a comparison with clofibrateAtherosclerosis, 1981
- Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogensNature, 1980
- Metabolic Effects of a New Hypolipidemic Agent, CiprofibrateJournal of Pharmaceutical Sciences, 1979
- The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drugAtherosclerosis, 1979
- One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemiaAtherosclerosis, 1978
- Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemiaAtherosclerosis, 1978
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Heart, 1978
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977
- PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASEThe Lancet, 1975